Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
12.12.2022 - As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.LAS VEGAS, Dec. ... Seite 1
Gb Sciences Gb Sciences Inc Phytomedical Analytics For Research Optimization At Scale Andrea Small Howard Chief Science Officer Phytomedical Analytics
Source: wallstreet-online.de